Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Hauer, AC.
Laboratory diagnostics in chronic inflammatory bowel diseases.
MONATSSCHR KINDERH. 2020; 168(4): 314-322. Doi: 10.1007/s00112-020-00853-8 [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Hauer Almuthe

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Laboratory diagnostics are part of the recommended initial diagnostic work-up for suspected chronic inflammatory bowel disease (IBD) as well as for monitoring disease activity and treatment response. Basic laboratory parameters, such as the erythrocyte sedimentation rate (ESR), are used to determine disease-specific activity indices and more novel serological markers, e.g. antineutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) are used to differentiate between IBD entities. Currently, fecal calprotectin, the most broadly investigated fecal inflammatory marker to date, seems to be the relatively best surrogate marker, both initially and for assessment of disease activity and this can be largely attributed to its high sensitivity; however, endoscopic and histopathological evaluations are still mandatory in establishing the diagnosis and also for checking on current treatment paradigms, including treat to target and with respect to the ultimate treatment goal of mucosal healing. Because regular re-endoscopies cause a high burden on pediatric patients, the development of less invasive biomarkers correlating as closely as possible with mucosal features is particularly important. How long-standing routinely used parameters but also more novel and even experimentally applied serological, fecal and functional laboratory markers and diagnostic methods can be rated within this context and which diagnostic methods are undergoing trials are summarized in this article.

Find related publications in this database (Keywords)

Biomarkers

Serology

Calprotectin

Volatile organic compounds

Noninvasive testing

© Med Uni Graz • Impressum